Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1.
about
Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical SensingAptamers in diagnostics and treatment of viral infectionsUse of Aptamers as Diagnostics Tools and Antiviral Agents for Human VirusesSelection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cellsOne-step selection of Vaccinia virus-binding DNA aptamers by MonoLEXAptamer-targeted cell-specific RNA interferenceNucleic acid aptamers: clinical applications and promising new horizonsAn aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction.Aptamers in virology: recent advances and challenges.Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.HIV-1 subtype C unproductively infects human cardiomyocytes in vitro and induces apoptosis mitigated by an anti-Gp120 aptamer.Development, screening, and analysis of DNA aptamer libraries potentially useful for diagnosis and passive immunity of arboviruses.Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: implications for RNA-based therapeutics.Human immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets.An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site.Hi-Fi SELEX: A High-Fidelity Digital-PCR Based Therapeutic Aptamer Discovery Platform.UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype CAptamers for Targeted Drug DeliveryTherapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretroviralsNovel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.Aptamer-based therapeutics: new approaches to combat human viral diseasesUse of RNA in drug design.Application of aptamers for targeted therapeutics.Bioinformatic analysis of the contribution of primer sequences to aptamer structures.Cell-specific aptamers as emerging therapeutics.Novel approach to analyzing RNA aptamer-protein interactions: toward further applications of aptamers.Aptamers against pathogenic microorganisms.Interplay between Autophagy, Exosomes and HIV-1 Associated Neurological Disorders: New Insights for Diagnosis and Therapeutic Applications.HIV-1 envelope trimer has similar binding characteristics for carbohydrate-binding agents as monomeric gp120.Aptamers in HIV research diagnosis and therapy.Aptamers and Their Significant Role in Cancer Therapy and Diagnosis.
P2860
Q26825644-9AB42DCE-1DF3-413B-ABD1-0EF3C01C6C40Q27014527-1CF5DA1F-6800-4A8D-B990-7FEA5CAF33B1Q28079654-4659656B-F8D1-4360-BF07-A41D20D9492AQ30859838-8B3CA73E-4B09-4F41-8308-57024C744981Q33294137-9F5BDD7B-DF64-491E-BB2A-195F3204B61EQ33717239-275838C8-5540-4E8F-BE44-70A35B551362Q34028112-C481F73B-5B32-4720-ABC2-FDBB73802FB3Q34092668-DD86DF39-1972-4920-B250-5C471D6F8661Q34162383-21F6A2CF-7D5B-4C50-B323-9E5CDA6E921EQ34232003-942F3C95-3F5A-4270-8F49-16E1CD075600Q34362343-31F19920-804E-4749-A5CE-9EC634851437Q34475779-A8904F9D-48C2-4CFE-BDD2-2E520D586687Q34509294-F6788A69-E691-41A7-9BC3-7DD44CB179DCQ34664366-02C40CC1-1958-4DD1-9656-E60D1E4D438FQ35234289-2412EB99-B77E-4C49-AA33-1CCB34C1AA53Q35569583-559331C3-65EE-494C-B074-6BBDA991E126Q35943810-DDC9A337-C53D-4FAB-8885-ED6831FE0EF9Q36155891-44D9D0BD-1293-40C0-A9FC-E63E26181D15Q36839458-12A1BC14-8B1C-4BD0-BEBD-30DE68ED86DAQ37247615-F4C32EEB-AA8C-47C5-9790-FA68D021643EQ37305770-87C3D2B6-3EB3-4207-8EA1-E276073E2901Q37415958-C2DEE0D1-B610-4091-9CBA-6D352FECA3B8Q38089160-D6B18A0A-AADD-48B3-BCBC-AAF20F2E6185Q38096870-B96BD48A-A648-4076-A4B1-0BC9EB95F00FQ38289647-5F975560-6B10-4D4D-9E74-AC8D52511ABFQ38302347-5489C26C-1615-497C-9EA2-14CB2C134BDBQ38312544-B5B9C711-57FE-4751-8C72-D323F77BEC78Q38563672-AC3BC37C-1957-4484-B245-344FC98F8728Q39419450-22FBD68C-750D-4161-A4BE-D189E5C7E9A1Q44942815-C4A68CEF-6414-4334-B702-91862DB3105DQ50066811-5301D7FD-0A3F-439F-A551-B95EEB6C7717Q54457076-0FC32F9A-5469-4C66-A3C9-56608BBB872B
P2860
Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Structural characterization of ...... utralizes R5 strains of HIV-1.
@ast
Structural characterization of ...... utralizes R5 strains of HIV-1.
@en
Structural characterization of ...... utralizes R5 strains of HIV-1.
@nl
type
label
Structural characterization of ...... utralizes R5 strains of HIV-1.
@ast
Structural characterization of ...... utralizes R5 strains of HIV-1.
@en
Structural characterization of ...... utralizes R5 strains of HIV-1.
@nl
prefLabel
Structural characterization of ...... utralizes R5 strains of HIV-1.
@ast
Structural characterization of ...... utralizes R5 strains of HIV-1.
@en
Structural characterization of ...... utralizes R5 strains of HIV-1.
@nl
P2860
P50
P356
P1433
P1476
Structural characterization of ...... utralizes R5 strains of HIV-1.
@en
P2093
Antu K Dey
P2860
P304
P356
10.1261/RNA.7205405
P407
P577
2005-06-01T00:00:00Z